Stanford University Cancer Vaccine
Researchers at the Stanford University School of Medicine has added a milestone and major advancement in Medical Science by the discovery of cancer vaccine which eliminates tumors in mice.
A study by the researchers has indicated that injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases.
Stanford University Cancer Vaccine Update
During this work on the possible cancer treatment, it was observed that cancer therapy works for many different types of cancers, including those that arise spontaneously.
On the course of this study led by Stanford University researchers; Ronald Levy and Idit Sagiv-Barfi; it was believed that the local application of very small amounts of the agents could serve as a rapid and relatively inexpensive cancer therapy.
It’s unlikely to cause the adverse side effects often associated with body-wide immune stimulation.
“Our approach involved a one-time application of very small amounts of two agents to stimulate the immune cells only within the tumor itself. We noticed an amazing, body wide effects in the affected mice, including the elimination of tumors all over the animal”, Levy stated.
Stanford University Cancer Vaccine Testing
The approach worked startlingly well in laboratory mice with transplanted mouse lymphoma tumors in two sites on their bodies.
Injecting one tumor site with the two agents caused the regression not just of the treated tumor, but also of the second, untreated tumor.
87 of 90 Mice Were Cured of Cancer
In this way, 87 of 90 mice were cured of cancer. Although cancer recurred in three of the mice, the tumors again regressed after a second treatment.
Stanford Cancer Vaccine Human Trials & Results
The researchers saw similar results in mice bearing breast, colon and melanoma tumors.
One agent is currently already approved for use in humans; the other has been tested for human use in several unrelated clinical trials.
A clinical trial was launched in January to test the effect of the treatment in patients with lymphoma.
The method works by reactivation of the cancer-specific T cells.
The reactivation is achieved through injection of microgram amounts of two agents directly into the tumor site.
The first agent, a short stretch of DNA called a CpG oligonucleotide, works with other nearby immune cells. It amplifies the expression of an activating receptor called OX40 on the surface of the T cells.
While the second agent, an antibody that binds to OX40, activates the T cells to lead the charge against the cancer cells.
Because the two agents are injected directly into the tumor, only T cells that have infiltrated they are activated.
In effect, these T cells are “prescreened” by the body to recognize only cancer-specific proteins.
The work is an example of Stanford Medicine’s focus on precision health. The goal of which is to anticipate and prevent disease in the healthy. As well as precisely diagnose and treat disease in the ill.
The study’s other Stanford co-authors are senior research assistant and lab manager Debra Czerwinski; professor of medicine Shoshana Levy, Ph.D.; postdoctoral scholar Israt Alam, PhD; graduate student Aaron Mayer; and professor of radiology Sanjiv Gambhir, MD, PhD.